Psychemedics Corporation (PMD): Price and Financial Metrics


Psychemedics Corporation (PMD): $8.00

-0.12 (-1.48%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

PMD POWR Grades


  • Growth is the dimension where PMD ranks best; there it ranks ahead of 0% of US stocks.
  • PMD's strongest trending metric is Stability; it's been moving down over the last 75 days.
  • PMD ranks lowest in Growth; there it ranks in the 0th percentile.

PMD Stock Summary

  • With a market capitalization of $45,002,924, Psychemedics Corp has a greater market value than only 6.25% of US stocks.
  • PMD's current price/earnings ratio is 108.97, which is higher than 93.25% of US stocks with positive earnings.
  • Price to trailing twelve month operating cash flow for PMD is currently 45.5, higher than 89.32% of US stocks with positive operating cash flow.
  • Stocks that are quantitatively similar to PMD, based on their financial statements, market capitalization, and price volatility, are HAE, TCMD, BCOV, TREE, and LNN.
  • Visit PMD's SEC page to see the company's official filings. To visit the company's web site, go to www.psychemedics.com.

PMD Valuation Summary

  • In comparison to the median Healthcare stock, PMD's EV/EBIT ratio is 177.82% lower, now standing at -22.8.
  • Over the past 243 months, PMD's EV/EBIT ratio has gone down 85.4.
  • PMD's price/earnings ratio has moved down 143.8 over the prior 243 months.

Below are key valuation metrics over time for PMD.

Stock Date P/S P/B P/E EV/EBIT
PMD 2021-08-31 2.0 3.5 -31.7 -22.8
PMD 2021-08-30 1.9 3.3 -30.3 -21.9
PMD 2021-08-27 1.9 3.2 -29.3 -21.3
PMD 2021-08-26 1.9 3.3 -30.2 -21.9
PMD 2021-08-25 1.9 3.2 -29.4 -21.4
PMD 2021-08-24 1.8 3.1 -28.2 -20.6

PMD Growth Metrics

  • The 3 year net income to common stockholders growth rate now stands at 227.22%.
  • Its 5 year net income to common stockholders growth rate is now at -49.97%.
  • Its 5 year cash and equivalents growth rate is now at 98.22%.
Over the past 33 months, PMD's revenue has gone down $18,866,000.

The table below shows PMD's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 23.808 0.989 0.413
2021-06-30 22.309 -0.117 -1.433
2021-03-31 19.536 -4.083 -3.617
2020-12-31 21.36 -4.083 -3.859
2020-09-30 24.74 -4.275 -3.846
2020-06-30 29.418 -1.11 -2.062

PMD Stock Price Chart Interactive Chart >

Price chart for PMD

PMD Price/Volume Stats

Current price $8.00 52-week high $8.90
Prev. close $8.12 52-week low $4.13
Day low $8.00 Volume 2,007
Day high $8.31 Avg. volume 26,763
50-day MA $8.36 Dividend yield N/A
200-day MA $7.40 Market Cap 44.34M

Psychemedics Corporation (PMD) Company Bio


Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States and internationally. The company’s tests provide quantitative information that can indicate the approximate amount of drug ingested, as well as historical data, which can show a pattern of individual drug use over a longer period of time. The company was founded in 1985 and is based in Acton, Massachusetts.


PMD Latest News Stream


Event/Time News Detail
Loading, please wait...

PMD Latest Social Stream


Loading social stream, please wait...

View Full PMD Social Stream

Latest PMD News From Around the Web

Below are the latest news stories about Psychemedics Corp that investors may wish to consider to help them evaluate PMD as an investment opportunity.

Psychemedics: Q3 Revenues +29%, Margins Surge, Possible Corporate Actions Including Dividend

Psychemedics (PMD) reported a strong 3Q21 with revenue growth of 29.0% YoY that was driven by domestic revenues which were up 27% YoY. The domestic business showed good volume growth and key markets like oil and gas, manufacturing and transportation did well. Schools also showed some recovery. Off a small...

Value Investment Principals on Seeking Alpha | November 18, 2021

Returns On Capital At Psychemedics (NASDAQ:PMD) Paint A Concerning Picture

When it comes to investing, there are some useful financial metrics that can warn us when a business is potentially in...

Yahoo | November 16, 2021

Psychemedics Corporation Reports Stronger Revenue, Operating Profit and Earnings Growth in Third Quarter 2021

ACTON, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), the world’s largest provider of hair testing for drugs of abuse, today announced financial results for the third quarter ended September 30, 2021. The Company’s revenue for the quarter ended September 30, 2021, was $6.7 million versus $5.2 million for the quarter ended September 30, 2020, an increase of 29%. Net income for the quarter ended September 30, 2021, was $0.7 million or $0.13 per diluted share, versu

Yahoo | November 12, 2021

Psychemedics Corporation Reports Stronger Second Quarter 2021 Financial Results

ACTON, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ:PMD), the world’s largest provider of hair testing for drugs of abuse, today announced financial results for the second quarter ended June 30, 2021. The Company’s revenue for the quarter ended June 30, 2021, was $6.1 million versus $3.3 million for the quarter ended June 30, 2020, an increase of 85%. Net income for the quarter ended June 30, 2021, was $0.1 million or $0.02 per diluted share, versus net loss of $2.1

Yahoo | August 10, 2021

Did Psychemedics Corporation (NASDAQ:PMD) Insiders Buy Up More Shares?

We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that...

Yahoo | July 1, 2021

Read More 'PMD' Stories Here

PMD Price Returns

1-mo -3.73%
3-mo 3.23%
6-mo 20.30%
1-year 85.19%
3-year -49.95%
5-year -60.15%
YTD 57.17%
2020 -43.26%
2019 -38.19%
2018 -20.09%
2017 -14.14%
2016 152.68%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7899 seconds.